The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020
November 20, 2020 16:01 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today has been named...
Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics
August 03, 2020 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics Oxford, UK – 3 August...
Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results
March 30, 2020 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., March 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported recent...
Beam Therapeutics Announces Key R&D Appointments
March 16, 2020 07:00 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced key...